DoD Says AVI Biopharma's (AVII) Flu Drug Candidate Does Not Qualify for Contract Award
AVI Biopharma (Nasdaq: AVII) receives notice from Department of Defense its proposal for full clinical development of its influenza candidate, AVI-7100 did not qualify for a contract award.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LendingClub (LC) Adds Former Morgan Stanley, BlackRock Execs to Investor Group
- Lion Biotechnologies (LBIO) Enters Extended Agreement with CRADA; New Principal Accounting Officer Named
- Momenta Phama (MNTA), Teva (TEVA) Active as '250 Patent on Capoxone Invalid
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!